Overview of Sedorrhoide

Property	Description
Active Ingredients	Benzocaine, Dodeclonium Bromide, Enoxolone, Esculoside
Form	Rectal Cream, Suppository
Pharmacological Class	Anesthetic, Antiseptic, Anti-inflammatory, and Venotonic Combination
Common Use	Symptomatic relief of localized anorectal discomfort and inflammation
Origin	Synthetic and Naturally-Derived Compounds

What Kind of Pharmaceutical Preparation is Sedorrhoide?

Sedorrhoide is a specialized multi-component combination product formulated as a rectal preparation, distinguishing it as a medicine for strictly local application. It is available in suitable dosage form(s) for direct contact with the affected tissue, primarily as a suppository and a rectal cream. The product features a distinctive design, integrating four distinct active substances into a single formula to provide multi-modal symptomatic relief.

Sedorrhoide’s Composition and Comprehensive Pharmacological Class

The core identity of Sedorrhoide is defined by its four Active Pharmaceutical Ingredients (APIs): Benzocaine, Dodeclonium Bromide, Enoxolone, and Esculoside. Due to this integration, the drug achieves its comprehensive classification as an Anesthetic, Antiseptic, Anti-inflammatory, and Venotonic Combination product. Benzocaine serves as a local anesthetic for surface numbing, while Dodeclonium Bromide is classified as a quaternary ammonium compound with surface-cleansing properties. The inclusion of Esculoside, a derived glucoside that acts as a venotonic agent, provides a distinguishing characteristic, as this type of vascular support is beneficial in managing localized vascular fragility.

General Therapeutic Purpose of the Multi-Modal Formula

The general purpose of Sedorrhoide is to provide comprehensive, simultaneous symptomatic support through its powerful multi-modal formula and non-systemic action. The product is engineered for use in typical scenarios where there is a combination of localized pain, itching, and inflammation. The strategy is to deliver rapid discomfort relief while the integrated anti-inflammatory and venotonic components work concurrently to soothe irritation and support the microvascular integrity of the local tissue. This strategic combined local action is intended to address multiple causes of symptomatic distress directly at the site of application.

Regulatory References

European public assessment reports (EPARs)

What side effects are possible with Sedorrhoide?

Possible side effects and safety information

The officially documented adverse reactions for Sedorrhoide, a multi-component rectal preparation, are generally local and classified by regulatory frequency standards. These safety classifications are derived from prescribing information filed with government health authorities.

Classification of Official Adverse Reactions

The most frequently cited adverse reactions relate to local effects at the site of application, a pattern consistent with a topical medication.

Common/Uncommon Reactions: These include localized hypersensitivity reactions and local skin manifestations, such as a burning sensation, pruritus (itching), erythema (redness), or dermatitis (skin inflammation). These effects primarily involve the Skin and Subcutaneous Tissue Disorders system-organ class.
Serious Adverse Reactions (Rare): Due to the local anesthetic component, Benzocaine, there is a documented, though rare, potential for the serious systemic condition, Methemoglobinemia, which involves the Blood and Lymphatic System. This risk is heightened when used on extensive or damaged tissues, or over an extended duration, as systemic absorption increases.

Safety Considerations for Specific Populations

Regulatory documentation highlights specific safety constraints tied to the risk of systemic absorption of Benzocaine:

Pediatric Risk: Infants and very young children are identified as having increased susceptibility to the risk of Methemoglobinemia.
Genetic Susceptibility: Individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency are recognized as being more susceptible to developing drug-induced Methemoglobinemia.

These safety notes define the risk as being dose-dependent and constrained by the rate and extent of absorption from the application site.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Sedorrhoide is governed by the systemic risk associated with one of its active components, Benzocaine, specifically the potential for Acquired Methemoglobinemia. This is a documented, life-threatening blood disorder characterized by a severe reduction in the blood’s capacity to carry oxygen, which is classified as a potentially fatal outcome in regulatory communications.

Documented Manifestations and Severe Outcomes

Overdose manifestations that require urgent attention include the sudden onset of pale, gray, or blue-colored skin, lips, or nail beds (cyanosis). This is often accompanied by respiratory and neurological signs such as shortness of breath, confusion, headache, fatigue, and an increased rapid heart rate. These severe outcomes are the focus of official regulatory warnings.

Mandated Emergency Action

If any signs or symptoms of Methemoglobinemia are observed, government regulatory guidance mandates that patients seek medical attention immediately. The presentation of these specific symptoms establishes an acute emergency requiring prompt clinical evaluation and intervention. Management procedures described in the regulatory context involve symptomatic and supportive treatment.

Population-Specific Considerations

Certain individuals are documented to be at greater risk for this systemic event, including elderly patients, those with pre-existing breathing problems (such as asthma or emphysema), individuals with heart disease, and patients with certain inborn defects (e.g., G6PD deficiency). These populations should be observed for any signs of overdose following application.

Therapeutic Uses of Sedorrhoide

What Sedorrhoide Treats: Main Uses and Benefits

Sedorrhoide's therapeutic domain is the symptomatic treatment of localized anorectal discomfort. The medication is commonly used to help manage the painful and pruritic (itchy) manifestations associated with certain anal pathologies, particularly during a hemorrhoidal crisis.

The formula is relevant for easing acute sensory distress, which includes the sharp localized pain, intense burning, and persistent pruritus that often become more disruptive during flare-ups. Sedorrhoide assists with addressing inflammatory manifestations, such as tissue swelling and soreness, which are linked to irritative states, thereby supporting local tissue comfort.

Common uses include providing short-term symptomatic assistance for internal hemorrhoids, external hemorrhoids, and other related anal pathologies involving heightened discomfort. This action contributes to improved comfort during periods of heightened symptoms and helps ease the overall burden of distress.

Quick Fact: Relief for Acute Discomfort

The medication is commonly applied in scenarios where acute symptoms intensify and temporary relief is needed, assisting with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

Base de Données Publique des Médicaments (ANSM)

Eligibility and Restrictions for Use

Who can and cannot use Sedorrhoide? Official Regulatory Information

The eligibility for Sedorrhoide use is defined by specific rules documented in official government regulatory sources, which outline both absolute prohibitions and conditional restrictions.

Contraindicated Populations (Absolute Non-Eligibility)

Sedorrhoide is formally contraindicated and must not be used by any individual with a known allergy or hypersensitivity to Benzocaine, one of the active ingredients, or to any other component of the rectal formulation.

Restricted and Conditional Use

Pregnancy and Lactation: The medicine is officially not recommended for use by pregnant individuals or those who are breastfeeding.
Age-Group Limitations: Use in children and adolescents is restricted and contingent upon obtaining prior medical consultation. Adults are the implied population eligible for standard use.
Comorbidity Risk: Regulatory documents note that patients with predisposing medical conditions such as certain breathing problems, heart disease, or older adults may be at increased risk for complications related to the active ingredient Benzocaine.

Eligibility Status Summary

Regulatory documentation explicitly defines non-eligibility through absolute hypersensitivity contraindications and applies limitations—categorized as "not recommended" or "restricted/conditional use"—to specific life stages and the pediatric population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents from the French National Agency for the Safety of Medicines and Health Products (ANSM) state that, based on available data, there is no indication of clinically significant drug-to-drug interactions for Sedorrhoide (cream or suppository formulations). Despite this finding, individuals are advised to inform a healthcare professional, such as a doctor or pharmacist, about any other prescription or non-prescription medicines they are currently taking or have recently taken.

Specific interacting medicines or medicinal product classes are not explicitly listed in the official labeling as requiring restricted co-administration. Furthermore, the official documents state that interactions with food, drink, herbal products, or alternative therapies are not applicable to the product's use.

Procedural Interaction Note

A specific constraint included in the official labeling relates to the active ingredient benzocaine, a local anesthetic component. This substance may lead to a positive result in certain tests performed during anti-doping controls. Athletes or individuals undergoing such testing should be aware of this potential procedural interference.

Summary of Official Interaction Profile

Interaction Scope	Regulatory Statement
Interacting Medicines	No clinically significant interactions suggested by available data.
Foods/Herbal Products	Not applicable as an interaction category.
Laboratory/Test Interference	Benzocaine component may cause a positive reaction in anti-doping controls.

Mechanism of Action

The activity of Sedorrhoide is defined by the pharmacodynamic actions of four distinct components, each modulating a specific biological pathway at the site of application.

Modulating Local Sensory Nerve Conduction

One agent causes a localized interruption of nerve impulse conduction by acting directly on Voltage-gated Sodium Channels ( Nav) found in sensory neurons. By blocking these channels, the initiation and propagation of nerve impulses are halted, effectively halting the initiation and propagation of action potentials in sensory neurons.

Reinforcing the Anti-Inflammatory Cascade

Another component, Enoxolone, modulates the local Inflammatory Cascade by reversibly inhibiting the enzyme mathbf11beta -HSD2. This inhibition leads to a localized preservation and enhancement of the body's natural cortisol activity, a mechanism that suppresses the release of inflammatory mediators and contributes to the physiological mitigation of local edema and inflammatory response.

Stabilizing Microvascular Integrity

A third agent, Esculoside, exerts its action by improving the structural integrity of the Capillary Endothelium. This mechanism supports the microvascular barrier by reducing capillary fragility and inhibiting enzymes responsible for tissue degradation, which physiologically limits the extravasation of fluid.

Surface Antimicrobial Disruption

The final component, Dodeclonium Bromide, acts as a membrane disruptor. This mechanism results in disruption of microbial cellular structures on the surface, preventing microbial proliferation that could exacerbate inflammatory signaling.

Dosage and Administration Information

Administration Route and Regimen

Sedorrhoide is designed exclusively for local administration via the rectal route, reflecting its role as a short-term, multi-modal symptomatic treatment. The standard protocol for adult administration establishes a specific frequency based on the chosen dosage form.

The standard regimen for the Rectal Cream involves two to three applications per day. For internal administration, the usage instructions include the use of the applicator cannula supplied with the product to ensure proper delivery. Alternatively, when using the Suppository form, the standard adult regimen is set at two or three suppositories per 24-hour period.

Duration and Contextual Use

A critical parameter of use is the maximum treatment duration. The application of Sedorrhoide is typically limited to a short-term intervention, with continuous administration not exceeding 7 consecutive days. This time-bound use underscores its role as an acute aid.

The medication's standard dosing regimen is generally reserved for adults. Administering Sedorrhoide to pediatric patients necessitates prior consultation with a medical professional. Importantly, the general usage principle establishes that the administration of this product does not substitute for the specific treatment required to address the underlying anal pathology.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sedorrhoide

Evidence for Short-Term Symptomatic Relief in Hemorrhoidal Crisis

Sedorrhoide is a specialized combination product, and research exploring its use includes trials assessing short-term or episodic symptom patterns associated with conditions characterized by periods of heightened symptoms, such as hemorrhoidal crisis. To understand the research process for localized discomfort, studies generally include Randomized Controlled Trials (RCTs). These studies compare the therapeutic class of agents—components like local anesthetics and venotonics—against a placebo or another topical treatment.

Research primarily examines patient-reported outcomes describing perceived discomfort. These outcomes related to physical discomfort include measurements of localized pain, the burning sensation, and the intensity of itching (pruritus). Furthermore, studies evaluate objective signs, such as the degree of tissue swelling and the presence of bleeding, which are outcomes linked to inflammatory or irritative states. These studies are usually conducted during periods of increased symptom activity; research monitors how symptoms evolved in the observed populations.

Outcomes Measured in Clinical Studies

The clinical trials research examined how patients reported their experience and how symptoms change over defined time intervals. Outcomes reflecting daily functioning or activity level are also sometimes included in the research protocols. These patient-reported outcomes describing perceived discomfort help contextualize how patients reported their experience during the acute phase of heightened symptom activity. The evidence contributes to understanding symptom patterns; however, it does not determine whether an individual will respond similarly.

Research on Long-Term Use and Follow-Up Duration

Since Sedorrhoide was studied for conditions characterized by fluctuating or episodic manifestations, the available evidence primarily concerns short-term periods. The follow-up durations were limited in many of the core studies. Researchers often restrict the observation periods to only a few weeks, which is typical for products intended to manage an acute episode where symptoms may vary in intensity.

Consequently, long-term effects are not fully established. Research provides limited information for long-term outcomes or how often symptoms might return after the defined study observation interval. The evidence available describes temporary or acute changes and does not include comprehensive data on durability of response or the long-term pattern of recurrence over many months.

Evidence in Specific Patient Groups

The majority of the research for this class of topical agents was evaluated in general adult populations experiencing symptomatic hemorrhoids. However, some specialized studies research examined the use of similar combination therapies for specific patient subgroups. For instance, certain clinical trials have explored responses in women with hemorrhoidal symptoms associated with pregnancy or childbirth.

Key Limitations and What Remains Uncertain in the Research

The overall certainty remains low for the specific Sedorrhoide formulation because the evidence base is based on research examining the pharmacological class of its components—topical anesthetics and phlebotonics—or similar two- or three-component products. Comparative evidence is lacking for the specific four-component combination versus using simpler therapies.

Furthermore, the sample sizes were modest in some studies, and evidence quality varies across studies depending on the specific product and design. The available research provides context but not individual predictions. It highlights what is known—and what is still uncertain—about managing temporary episodes, acknowledging that the long-term effects are not fully established.

Key Studies & References SEDORRHOIDE CRISE HEMORROIDAIRE, crème rectale - Base de Données Publique des Médicaments (Public Database of Medicines)

Frequently Asked Questions (FAQ)

Common questions about Sedorrhoide (FAQ)

Q: Is Sedorrhoide cream used for external hemorrhoids, or only internal ones?

A: The official product information states that the rectal cream is used for both external and internal hemorrhoids. For external use, it is applied directly to the affected area. For internal administration, the usage instructions state the applicator cannula supplied with the product should be used.

Q: What is the intended purpose of the suppository form of Sedorrhoide?

A: According to official regulatory documents, the suppository is intended for the rectal route to deliver the medicine directly to the affected area. Its intended purpose is to contribute to the symptomatic relief of localized discomfort, such as pain, burning, and itching, particularly during an acute hemorrhoidal crisis.

Q: What is a 'local anesthetic' in simple terms, and why is it included in Sedorrhoide?

A: Sedorrhoide includes Benzocaine, which is classified as a local anesthetic. A local anesthetic is included in the formula for its described action of blocking nerve impulses to help relieve pain and localized discomfort.

Q: Is Sedorrhoide used for anal fissures as well as hemorrhoids?

A: The official indication for Sedorrhoide is the symptomatic treatment of painful and pruritic (itchy) anal manifestations, especially in a hemorrhoidal crisis. The stated purpose covers the relief of pain and itching associated with certain anal pathologies, but the medicine is pre-conized for hemorrhoidal crisis.

Q: Is Sedorrhoide described as a cure or permanent treatment for hemorrhoids?

A: Sedorrhoide is explicitly described in official documents as a symptomatic treatment and a short-term intervention. It is intended only for use during an acute crisis and is not considered a cure or a permanent treatment for hemorrhoids.

Q: How quickly is Sedorrhoide generally expected to provide symptomatic relief?

A: The official documentation suggests that relief is expected to begin as soon as the first application, which is due to the local effects of the active ingredients delivered directly at the site of application. Sedorrhoide is classified for use during an acute phase of symptoms.

Q: What is the expected duration of relief after a single application of Sedorrhoide?

A: The official dosing regimen requires two to three applications or suppositories per day. This frequency suggests that the effect of a single application may require re-application approximately every 8 to 12 hours to sustain symptomatic relief.

Q: What is a Methemoglobinemia reaction and what are its symptoms?

A: Methemoglobinemia is a documented rare risk associated with the local anesthetic component, Benzocaine. The condition affects the red blood cells, reducing their capacity to carry oxygen in the blood. Symptoms of methemoglobinemia are generally characterized by a reduction in the blood’s ability to carry oxygen, which can manifest as changes in skin color, headache, or dizziness.

Q: What patient action is recommended if side effects from Sedorrhoide worsen or persist?

A: Official regulatory documents state that if any side effects are noticed that are not mentioned in the official leaflet, or if any side effects become severe or persist, the doctor or pharmacist should be informed.

Q: Does the product label contain warnings about interactions with food, drink, or herbal products?

A: According to the official product labeling, interactions with food, drink, or herbal products are listed as not applicable to the use of Sedorrhoide. This means no specific warnings in these categories are present in the official documentation.

Q: How does a product like Sedorrhoide (topical) differ from oral hemorrhoid treatments?

A: Sedorrhoide is designed as a topical preparation for local application via the rectal route. This local action is intended to provide symptomatic relief directly at the affected site, contrasting with oral treatments which typically have a systemic action throughout the body.

Q: Is Sedorrhoide considered a venoactive drug?

A: Yes, Sedorrhoide is classified as a venotonic combination product. This classification is due to the presence of the active ingredient Esculoside, which officially supports the microvascular integrity of the blood vessel walls.

Q: What are the potential consequences of using more than the recommended dosage (overdose)?

A: While official documents state that no cases of overdose have been reported, using more than the recommended dosage may potentially lead to an exacerbation of the known adverse effects. Excessive use may potentially lead to an exacerbation of the known local adverse effects.

Q: What steps are officially required for safe storage of Sedorrhoide?

A: Official instructions state that Sedorrhoide should be kept out of the reach and sight of children and should not be used after the expiry date shown on the packaging. Otherwise, the product does not require special storage precautions.

Q: What is the correct way to dispose of unused or expired Sedorrhoide?

A: To ensure proper environmental protection, official instructions prohibit the disposal of unused or expired medicine in the household waste or down the drain. Instead, regulatory documents state that the product should be returned to a pharmacist for safe disposal.

Q: What does 'symptomatic treatment' mean for Sedorrhoide?

A: 'Symptomatic treatment' is the official description of Sedorrhoide's purpose. This means the medicine is used to relieve the unpleasant signs of an illness, such as pain, burning, or itching, rather than addressing the underlying disease or cause itself.

Q: What is the information available about using Sedorrhoide if a person has G6PD Deficiency?

A: Regulatory safety information indicates that individuals with a Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency are recognized as being more susceptible to the rare risk of Methemoglobinemia. The increased susceptibility to Methemoglobinemia is associated with the product’s local anesthetic component.

Q: What are the main purposes of the different components in the cream versus the suppository?

A: Both the rectal cream and suppository formulations contain the same four active ingredients. The difference between the two lies in the inactive components, known as excipients, which are used to achieve the necessary consistency and form required for the specific route of administration.

Q: Is Sedorrhoide expected to stop bleeding associated with hemorrhoids?

A: The medicine is designed to reduce symptomatic manifestations of a hemorrhoidal crisis. Official documentation indicates that the symptomatic manifestations that Sedorrhoide addresses can include minor bleeding associated with the localized inflammation and irritation.

How should Sedorrhoide be stored and disposed of?

How to Store and Dispose of Sedorrhoide

Official regulatory documentation defines specific, mandatory requirements for storing and disposing of Sedorrhoide cream and suppositories.

Storage Requirements

Sedorrhoide does not require special precautions for storage, indicating stability under normal conditions. Crucially, the product must be kept out of the reach and sight of children. The medicine must not be used after the expiry date shown on the outer packaging.

Disposal Instructions

To ensure proper environmental protection, the regulatory labeling prohibits disposal of Sedorrhoide in the sewer or household waste (trash). Instead, unused or expired medicine must be returned to a pharmacist for safe and controlled disposal.

Sedorrhoide